Suppr超能文献

作为治疗溃疡性结肠炎的潜在药物:当前证据的综合评价。

as a potential drug in the treatment of ulcerative colitis: a comprehensive review of current evidence.

机构信息

School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Department of Pharmacy, Sichuan Provincial Orthopedic Hospital, Chengdu, China.

出版信息

Pharm Biol. 2024 Dec;62(1):818-832. doi: 10.1080/13880209.2024.2415652. Epub 2024 Oct 30.

Abstract

CONTEXT

Ulcerative colitis (UC) is an intractable inflammatory bowel disease that threatens the health of patients. The limited availability of therapeutic strategies makes it imperative to explore more efficient and safer drugs. (IN) is a traditional Chinese medicine that possesses many pharmacological activities, including anti-inflammatory, antioxidant, and immunomodulatory activities. The treatment potential of IN for UC has been proven by numerous preclinical and clinical studies in recent years.

OBJECTIVE

This article provides a comprehensive review of the utility and potential of IN in the treatment of UC.

METHODS

'Indigo naturalis' 'Qing dai' 'Qingdai' 'Ulcerative colitis' and 'UC' are used as the keywords, and the relevant literature is collected from online databases (Elsevier, PubMed, and Web of Science).

RESULTS AND CONCLUSION

Indirubin, indigo, isatin, tryptanthrin, and β-sitosterol are considered the key components in the treatment of UC with IN. Both preclinical and clinical studies support the efficacy of IN for UC, especially in severe UC or in those who do not respond to or have poor efficacy with existing therapies. The mechanisms of IN for UC are associated with the aryl hydrocarbon receptor pathway activation, immune regulation, oxidative stress inhibition, and intestinal microbial modulation. However, the clinical use of IN has the risks of adverse events such as pulmonary hypertension, which suggests the necessity for its rational application. As a potential therapeutic agent for UC that is currently receiving more attention, the clinical value of IN has been initially demonstrated and warrants further evaluation.

摘要

背景

溃疡性结肠炎(UC)是一种严重威胁患者健康的难治性炎症性肠病。治疗策略有限,因此迫切需要探索更有效和更安全的药物。靛蓝是一种传统中药,具有多种药理活性,包括抗炎、抗氧化和免疫调节作用。近年来,大量的临床前和临床研究证明了靛蓝治疗 UC 的潜力。

目的

本文全面综述了靛蓝在治疗 UC 中的应用和潜力。

方法

以“Indigo naturalis”“Qing dai”“Qingdai”“Ulcerative colitis”和“UC”为关键词,从在线数据库(Elsevier、PubMed 和 Web of Science)中收集相关文献。

结果与结论

靛玉红、靛蓝、靛红、色胺酮和β-谷甾醇被认为是靛蓝治疗 UC 的关键成分。临床前和临床研究均支持靛蓝治疗 UC 的疗效,尤其是在重度 UC 或对现有治疗反应不佳或疗效不佳的患者中。靛蓝治疗 UC 的机制与芳香烃受体通路激活、免疫调节、氧化应激抑制和肠道微生物调节有关。然而,靛蓝的临床应用存在肺动脉高压等不良反应的风险,这表明需要合理应用。作为一种目前受到更多关注的 UC 潜在治疗药物,靛蓝的临床价值已初步得到证实,值得进一步评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/11533244/9caf833f628e/IPHB_A_2415652_F0001_B.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验